Lucid’s Cellular Imaging Technology part of German Association of Scientific Medical Societies Dermatological Guidelines

March 19, 2012–ROCHESTER, N.Y.–(BUSINESS WIRE)–Lucid, Inc. (OTC/BB: LCDX.OB, LCDXW.OB) today announces the publication of the Association of Scientific Medical Societies (AWMF) S1 guideline on the use of confocal laser scanning microscopy (CLSM) for dermatological applications. This recommendation on the part of the Medical Societies in Germany provides users with the first uniform recommendations for the use of this technology. Further, the guideline confirms the importance of CLSM in dermatological diagnostic applications and embraces that use of this innovative procedure in routine clinical dermatology practice.

The “Confocal Laser Microscopy in Dermatology” guidelines published by the AWMF under the auspices of the German Dermatological Society (DDG), for the first time combines the extensive knowledge of practical application and clinical research. In addition to information about the operating principles of CLSM and the currently available devices (VivaScope 1500, VivaScope 1500 Multilaser, VivaScope 3000 and VivaScope 2500 Multilaser, commercially available in Europe, the Middle East and Northern Africa from Lucid’s business partner, MAVIG, and in the rest of the world from Lucid directly), the guidelines also contain detailed explanations of examination and diagnostic techniques along with evidence-based findings in the most important in vivo and ex vivo application areas.

“The publication of the S1 guideline is an important milestone for confocal laser scanning microscopy,” states Professor Julia Welzel, MD, a dermatology and venereology specialist at Augsburg Hospital and co-author of the guideline. “The recommendations represent a significant simplification for all users and make an important contribution to the standardization of diagnostics with the VivaScope devices.” Starting with the depiction of healthy skin, the authors describe the steps required for the in vivo diagnosis of skin tumors such as malignant melanoma, actinic keratosis and basal cell carcinoma. The guidelines also discuss the diagnosis of inflammatory dermatoses as well as pathogen diagnostics such as with the mite infestation or in cases of infections caused by fungi, bacteria and viruses, along with the various applications in cosmetic research. The chapter on ex vivo diagnostics focuses on the study of edge incisions within the scope of a micrographically controlled surgery for tumor excisions; such as the Mohs Micrographic Surgery common in dermatology.

About Lucid, Inc.

Lucid, Inc. is a leader in noninvasive skin cancer imaging and diagnosis through the use of its FDA cleared VivaScope® confocal imagers and its innovative VivaNet® telepathology system that allows secure, HIPAA compliant, near real-time collaboration between dermatologists and pathologists. VivaNet® provides rapid online medical image transfer storage and retrieval, enabling critical collaborative consultations at the point and time of care. Lucid’s VivaScopes® provide images that physicians can use to assist in forming medical decisions in cases of melanoma and other skin cancers while ensuring patient comfort and peace of mind. You can learn more about the Company and its innovative products at www.lucid-tech.com.

VivaScope® and VivaNet® are registered trademarks of Lucid, Inc.

Safe Harbor

This press release contains “forward looking statements” within the meaning of the Securities Litigation Reform Act of 1995. These statements include but are not limited to our plans, objectives, expectations and intentions and other statements that contain words such as “expects,” “contemplates,” “anticipates,” “plans,” “intends,” “believes,” “assumes” and variations of such words or similar expressions that predict or indicate future events or trends, or that do not relate to historical matters. These statements are based on our current beliefs or expectations and are inherently subject to significant known and unknown uncertainties and changes in circumstances, many of which are beyond our control. There can be no assurance that our beliefs or expectations will be achieved and actual results may differ materially from our beliefs or expectations due to financial, economic, business, regulatory and other factors or conditions affecting us or our industry in general, as well as more specific risks and uncertainties facing us, such as those set forth in the Risk Factors section of the final prospectus dated December 27, 2011.

Contacts

Lucid, Inc.
Martin Joyce, 857-263-7646
or
Investors:
LHA, Inc.
Kim Sutton Golodetz, 212-838-3777
kgolodetz@lhai.com
or
Bruce Voss, 310-691-7100
bvoss@lhai.com
@LHA_IR_PR